3 results
The primary objective of the trial is to evaluate whether L-BLP25 administered as weekly subcutaneous vaccinations with or without pretreatment with intravenous cyclophosphamide (CPA) induces a change in immune response parameters (ELISpot against…
The purpose of this study is to investigate how well a new dosage form of tildrakizumab is tolerated when it is administered to healthy volunteers. Tildrakizumab (also known as Ilumetri) is no new compound; it is already available on the market as a…
In this study we will investigate how safe the new compound seltorexant is and how well it is tolerated when it is used by healthy participants.We also investigate how quickly and to what extent seltorexant is absorbed, transported, and eliminated…